- Wednesday,
March 24th - 3:30 p.m.
EST -
MISSISSAUGA, ON, March 11, 2021 /PRNewswire/ - Nuvo
Pharmaceuticals® Inc. (TSX: MRV) (OTCQX: MRVFF) d/b/a
Miravo Healthcare (Miravo or the Company), a Canadian focused
healthcare company with global reach and a diversified portfolio of
commercial products, today announced Jesse
Ledger, Miravo's President & Chief Executive Officer and
Kelly Demerino, Miravo's Interim
Chief Financial Officer will be presenting at the Q1 Virtual
Investor Summit.
DATE:
|
Wednesday, March
24th, 2021
|
TIME:
|
3:30 p.m.
EST
|
COMPLIMENTARY
REGISTRATION:
|
https://zoom.us/webinar/register/WN_UHhzwEv6S3yGbrIbhK18Hw
|
About The Investor Summit
The Investor Summit
(formerly MicroCap Conference) is an exclusive, independent
conference dedicated to connecting smallcap and microcap companies
with qualified investors. The Q1 Investor Summit will take place
virtually, featuring 100 companies and over 300 institutional and
retail investors.
Please visit the website at www.investorsummitgroup.com
About Miravo Healthcare
Miravo is a Canadian focused,
healthcare company with global reach and a diversified portfolio of
commercial products. The Company's products target several
therapeutic areas, including pain, allergy, neurology and
dermatology. The Company's strategy is to in-license and acquire
growth-oriented, complementary products for Canadian and
international markets. Miravo's head office is located in
Mississauga, Ontario, Canada, the
international operations are located in Dublin, Ireland and the Company's
manufacturing facility is located in Varennes, Québec, Canada. The Varennes
facility operates in a Good Manufacturing Practices (GMP)
environment respecting the U.S, Canada and E.U. GMP regulations and is
regularly inspected by Health Canada and the U.S. Food and Drug
Administration. For additional information, please visit
www.miravohealthcare.com.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/miravo-healthcare-to-present-at-q1-virtual-investor-summit-301245111.html
SOURCE Nuvo Pharmaceuticals Inc.